PLRX Projected Dividend Yield
Pliant Therapeutics Inc ( NASDAQ : PLRX )Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avß6 and avß1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc. 21 YEAR PERFORMANCE RESULTS |
PLRX Dividend History Detail PLRX Dividend News PLRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |